Beyond ACEis and ARBs: The Promise of SGLT2 Inhibition to Reduce Risk of ESRD and Dialysis in Numerous Patient Populations
December 5, 2022
December 5, 2023
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with Kidney Disease: Improving Global Outcomes (KDIGO).
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other health care professionals completing this course will be issued a statement of participation.
The educational design of this activity addresses the needs of nephrologists, cardiologists, endocrinologists, internal medicine physicians, primary care physicians, nurse practitioners and physician assistants. Secondary audiences include clinical pharmacists, nurses, and other clinicians who care for patients who are at risk for CKD or at high risk of progression.
Statement of Need/Overview
Recently, SGLT2 inhibitors have been shown to slow the progression of chronic kidney disease (CKD), independent of whether the patient has diabetes. However, CKD is a silently progressive disease and most patients do not have their kidney function evaluated regularly, leaving many patients with CKD that is not recognized until it is in an advanced stage.
Join a panel of expert clinicians to explore strategies to recognize predisposing risk factors for CKD and improve the timeliness of referrals to specialists. Panelists will review the most recent data on SGLT2 inhibitors in advanced kidney disease and demonstrate how to apply that evidence in a variety of patient scenarios. Clinicians will learn about dosage and titration, use of SGLT2 inhibitors with RAS inhibition, and impacts on blood pressure, intraglomerular pressure, and hyperfiltration.
Upon completion of this activity, participants should be better able to:
- Develop strategies for multidisciplinary care team members to assess kidney function in high-risk people because of race/ethnicity and/or the presence of predisposing conditions
- Summarize the evidence supporting the impact of SGLT2 inhibitors on the progression of CKD, including conversion to end-stage renal disease (ESRD), in patients with advanced CKD independent of impacts on co-existing conditions
- Describe the mechanisms by which SGLT2 inhibitors slow down progression of CKD to ESRD, including impacts on blood pressure, intraglomerular pressure, and hyperfiltration
Ramy M. Hanna, MD, FASN, FACP, FNKF
Associate Professor of Medicine – I
Fellowship Program Director
University of California, Irvine
Silvio E. Inzucchi, MD
Professor of Medicine
Clinical Chief, Endocrinology
Medical Director, Yale Diabetes Center
Yale School of Medicine
Yale New Haven Hospital
Meg J. Jardine, MD, PhD, FRACP
University of Sydney
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
- Ramy M. Hanna, MD, FASN, FACP, FNKF
- Contracted Research: Alexion, Appelis, Otsuka, Remegen, Roche
- Speakers’ Bureau: Alexion, Aurinia, AstraZeneca, GSK, Otsuka
- Silvio E. Inzucchi, MD
- Consulting Fee (e.g., Advisory Board): Abbott, AstraZeneca, Bayer, Boehringer Ingelheim/Lilly, Esperion, Lexicon, Merck/Pfizer, Novo Nordisk, VTV Therapeutics
- Honoraria: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim/Lilly, Esperion, Lexicon, Merck/Pfizer, Novo Nordisk, VTV Therapeutics
- Meg J. Jardine, MD, PhD, FRACP
- Consulting Fee (e.g., Advisory Board): Akebia, AstraZeneca, Baxter, Bayer, Boehringer Ingelheim, Chinook Therapeutics, CSL Behring, Janssen, Vifor
- Contracted Research: Amgen, Baxter, CSL, Dimerix, Eli Lilly, Gambro, MSD
- Honoraria: Amgen, AstraZeneca, Janssen, Merck, MSD, Roche, Vifor
The planners and managers have the following relevant financial relationships with ineligible companies:
Lindsay Borvansky, has nothing to disclose.
Andrea Funk, has nothing to disclose.
Liddy Knight, has nothing to disclose.
Ashley Cann, has nothing to disclose.
Lauren Sinclair, has nothing to disclose.
Jaimee Harris-Gold, has nothing to disclose.
Terry Glauser, has nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.
There is no fee for this educational activity.
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com
For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive or CardioCareLive at 877-394-1306 or at Support@ClinicalSeriesLive.com.
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at support@PlatformQHealth.com
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting support@PlatformQHealth.com with the subject line “Data Request”